Amyotrophic lateral sclerosis and the clinical potential of dexpramipexole

References

• HirtzDThurmanDJGwinn-HardyKMohamedMChaudhuriARZalutskyRHow common are the common neurologic disorders?Neurology20076832633717261678
   PubMed Web of Science ®Google Scholar
• AnnegersJFAppelSLeeJRPerkinsPIncidence and prevalence of amyotrophic lateral sclerosis in Harris County, Texas, 1985–1988Arch Neurol1991485895932039380
   PubMed Web of Science ®Google Scholar
• BeghiEMillulAMicheliAVitelliELogroscinoGIncidence of ALS in Lombardy, ItalyNeurology20076814114517210896
   PubMed Web of Science ®Google Scholar
• MarinBGilJPreuxPMFunalotBCouratierPIncidence of amyotrophic lateral sclerosis in the Limousin region of France, 1997–2007Amyotroph Lateral Scler20091021622019452307
   PubMed Web of Science ®Google Scholar
• AlonsoALogroscinoGJickSSHernanMAIncidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based studyEur J Neurol20091674575119475756
   PubMed Web of Science ®Google Scholar
• ChioAMoraGCalvoAMazziniLBottacchiEMutaniREpidemiology of ALS in Italy: a 10-year prospective population-based studyNeurology20097272573119237701
   PubMed Web of Science ®Google Scholar
• RingholzGMAppelSHBradshawMCookeNAMosnikDMSchulzPEPrevalence and patterns of cognitive impairment in sporadic ALSNeurology20056558659016116120
   PubMed Web of Science ®Google Scholar
• GordonPHDelgadilloDPiquardAThe range and clinical impact of cognitive impairment in French patients with ALS: a cross-sectional study of neuropsychological test performanceAmyotroph Lateral Scler20111237237821585273
   PubMed Web of Science ®Google Scholar
• BlascoHGuennocAMVeyrat-DurebexCAmyotrophic lateral sclerosis: A hormonal condition?Amyotroph Lateral Scler2012 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• GautierGVerschuerenAMonnierAAttarianSSalort-CampanaEPougetJALS with respiratory onset: clinical features and effects of non-invasive ventilation on the prognosisAmyotroph Lateral Scler20101137938220001486
   PubMed Web of Science ®Google Scholar
• RavitsJMLa SpadaARALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degenerationNeurology20097380581119738176
   PubMed Web of Science ®Google Scholar
• LogroscinoGTraynorBJHardimanODescriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issuesJ Neurol Neurosurg Psychiatry20087961118079297
   PubMed Web of Science ®Google Scholar
• WijesekeraLCLeighPNAmyotrophic lateral sclerosisOrphanet J Rare Dis20094319192301
   PubMed Web of Science ®Google Scholar
• GordonPHCorciaPLacomblezLDefining survival as an outcome measure in ALSArch Neurol20096675876119506136
   PubMed Web of Science ®Google Scholar
• TraynorBJCoddMBCorrBFordeCFrostEHardimanOAmyotrophic lateral sclerosis mimic syndromes: a population based studyArch Neurol20005710911310634456
   PubMed Web of Science ®Google Scholar
• LeighPNAbrahamsSAl-ChalabiAThe management of motor neurone diseaseJ Neurol Neurosurg Psychiatry200374Suppl 4iv32iv4714645465
   PubMedGoogle Scholar
• BrooksBRMillerRGSwashMMunsatTLEl Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosisAmyotroph Lateral Scler Other Motor Neuron Disord2000129329911464847
   PubMed Web of Science ®Google Scholar
• De CarvalhoMDenglerREisenAElectrodiagnostic criteria for diagnosis of ALSClin Neurophysiol200811949750318164242
   PubMed Web of Science ®Google Scholar
• BoekesteinWAKleineBUHagemanGSchelhaasHJZwartsMJSensitivity and specificity of the ‘Awaji’ electrodiagnostic criteria for amyotrophic lateral sclerosis: retrospective comparison of the Awaji and revised El Escorial criteria for ALSAmyotroph Lateral Scler20101149750120536375
   PubMed Web of Science ®Google Scholar
• NelsonLMMcGuireVLongstrethWTJrMatkinCPopulation-based case-control study of amyotrophic lateral sclerosis in western Washington State. I. Cigarette smoking and alcohol consumptionAm J Epidemiol200015115616310645818
   PubMed Web of Science ®Google Scholar
• AndersenPMAl-ChalabiAClinical genetics of amyotrophic lateral sclerosis: what do we really know?Nat Rev Neurol2011760361521989245
   PubMed Web of Science ®Google Scholar
• GurneyMEPuHChiuAYMotor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutationScience1994264177217758209258
   PubMed Web of Science ®Google Scholar
• RowlandLPShneiderNAAmyotrophic lateral sclerosisN Engl J Med20013441688170011386269
   PubMed Web of Science ®Google Scholar
• RothsteinJDCurrent hypotheses for the underlying biology of amyotrophic lateral sclerosisAnn Neurol200965Suppl 1S3S919191304
   PubMed Web of Science ®Google Scholar
• GordonPHMeiningerVHow can we improve clinical trials in amyotrophic lateral sclerosisNat Rev Neurol2011765065421947135
   PubMed Web of Science ®Google Scholar
• JohriABealMFMitochondrial dysfunction in neurodegenerative diseasesJ Pharmacol Exp Ther6132012 [Epub ahead of print.]
   PubMed Web of Science ®Google Scholar
• MenziesFIncePGShawPJMitochondrial involvement in amyotrophic lateral sclerosisNeurochem Int20024054355111850111
   PubMed Web of Science ®Google Scholar
• AfifiAKAleuFPGoodgoldJMcKayBUltrastructure of atrophic muscle in amyotrophic lateral sclerosisNeurology1966164754815949060
   PubMed Web of Science ®Google Scholar
• BowlingACSchulzJBBrownHRJrBealMFSuperoxide dismutase activity, oxidative damage and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosisJ Neurochem199361232223258245985
   PubMed Web of Science ®Google Scholar
• CozzolinoMFerriAValleCCarriMTMitochondria and ALS: implications form novel gene and pathwaysMol Cell Neurosci2012 [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• ShiPGalJKwinterDMLiuXZhuHMitochondrial dysfunction in amyotrophic lateral sclerosisBiochim Biophys Acta20101892455119715760
   PubMed Web of Science ®Google Scholar
• CheahBCKiernanMDexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosisI Drugs20101391192021154151
   PubMed Web of Science ®Google Scholar
• BensimonGLacomblezLMeiningerVA controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study GroupN Engl J Med19943305855918302340
   PubMed Web of Science ®Google Scholar
• LacomblezLBensimonGLeighPNGuilletPMeiningerVDose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group IILancet19963479013142514318676624
   PubMed Web of Science ®Google Scholar
• MorrenJAGalvez-JimenezNCurrent and prospective disease-modifying therapies for amyotrophic lateral sclerosisExpert Opin Investig Drugs201221297320
   PubMed Web of Science ®Google Scholar
• MillerRGMitchellJDMooreDHRiluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)Cochrane Database Syst Rev20123CD00144722419278
   PubMed Web of Science ®Google Scholar
• RothsteinJDTherapeutic horizons for amyotrophic lateral sclerosisCurr Opin Neurobiol199666796878937834
   PubMed Web of Science ®Google Scholar
• BozikMMatherJLKrammerWGGribkoffVKIngershollEWSafety, tolerability and pharmacokinetics of KNS-760704 (Dexpramipexole) in healthy adult subjectsJ Clin Pharmacol2011511177118520959524
   PubMed Web of Science ®Google Scholar
• ChioABottacchiEBuffaCMutaniRMoraGPositive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilitiesJ Neurol Neurosurg Psychiatry20067794895016614011
   PubMed Web of Science ®Google Scholar
• AboussouanLSKhanSUBanerjeeMArroligaACMitsumotoHObjective measures of the efficacy of noninvasive positive-pressure ventilation in amyotrophic lateral sclerosisMuscle Nerve20012440340911353427
   PubMed Web of Science ®Google Scholar
• BourkeSCTomlinsonMWilliamsTLBullockREShawPJGibsonGJEffects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trialLancet Neurol2006514014716426990
   PubMed Web of Science ®Google Scholar
• ChioAFinocchiaroEMeineriPBottacchiESchifferDSafety and factors related to survival after percutaneous endoscopic gastrostomy in ALS. ALS Percutaneous Endoscopic Gastrostomy Study GroupNeurology1999531123112510496278
   PubMed Web of Science ®Google Scholar
• RowlandLPDr. Rowland’s six levels of hope. ALSD33 ALS-On-Line. ALS Interest GroupALS Digest #3325271997
   Google Scholar
• CudkowiczMEShefnerJMSchoenfeldDANortheast ALS Consortium. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosisNeurology20036145646412939417
   PubMed Web of Science ®Google Scholar
• MillerRGMooreDHGelinasDFPhase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosisNeurology20015684384811294919
   PubMed Web of Science ®Google Scholar
• FornaiFLongonePCafaroLLithium delays progression of amyotrophic lateral sclerosisProc Natl Acad Sci U S A20081052052205718250315
   PubMed Web of Science ®Google Scholar
• AggarwalSPZinmanLSimpsonENortheast and Canadian Amyotrophic Lateral Sclerosis consortia. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trialLancet Neurol2010948148820363190
   PubMed Web of Science ®Google Scholar
• ChiòABorgheroGCalvoALithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trialNeurology20107561962520702794
   PubMed Web of Science ®Google Scholar
• MillerRGMooreDHForshewDAPhase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial designNeurology20117797397921813790
   PubMed Web of Science ®Google Scholar
• GordonPHMooreDHMillerRGEfficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trialLancet Neurol200761045105317980667
   PubMed Web of Science ®Google Scholar
• CudkowiczMEShefnerJMSchoenfeldDATrial of celecoxib in amyotrophic lateral sclerosisAnn Neurol200660223116802291
   PubMed Web of Science ®Google Scholar
• MeiningerVBensimonGBradleyWREfficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trialsAmyotroph Later Scler20045107117
   PubMed Web of Science ®Google Scholar
• MeiningerVDroryVELeighPNLudolphARobberechtWSilaniVGlatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double-blind, randomized, multicentre, placebo-controlled trialAmyotroph Lateral Scler20091037838319922128
   PubMed Web of Science ®Google Scholar
• LudolphACBendottiCBlaugrundEGuidelines for preclinical animal research in ALS/MND: A consensus meetingAmyotroph Lateral Scler201011384520184514
   PubMed Web of Science ®Google Scholar
• CheungYKGordonPHLevinBSelecting promising ALS therapies in clinical trialsNeurology2006671748175117130405
   PubMed Web of Science ®Google Scholar
• GordonPHCheungYKLevinBA novel, efficient, randomized selection trial comparing combinations of drug therapy for ALSAmyotroph Lateral Scler2008921222218608093
   PubMed Web of Science ®Google Scholar
• LevyGKaufmannPBuchsbaumRA two-stage design for a phase II clinical trial of coenzyme Q10 in ALSNeurology20066666066316534103
   PubMed Web of Science ®Google Scholar
• AlbrechtSBuergerEPotential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexoleCurr Med Res Opin2009252977298719842998
   PubMed Web of Science ®Google Scholar
• ShannonKMBennettJPJrFriedmanJHEfficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study GroupNeurology1997497247289305331
   PubMed Web of Science ®Google Scholar
• KushidaCAPramipexole for the treatment of restless legs syndromeExpert Opin Pharmacother2006744145116503816
   PubMed Web of Science ®Google Scholar
• WahlFRenouEMaryVStutzmannJMRiluzole reduces brain lesions and improves neurological function in rats after a traumatic brain injuryBrain Res19977562472559187339
   PubMed Web of Science ®Google Scholar
• SethyVHWuHOostveenJAHallEDNeuroprotective effects of the dopamine agonists pramipexole and bromocriptine in 3-acetylpyridine-treated ratsBrain Res19977541811869134974
   PubMed Web of Science ®Google Scholar
• CassarinoDSFallCPSmithTSBennettJPJrPramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ionJ Neurochem1998712953019648878
   PubMed Web of Science ®Google Scholar
• SayeedIParvezSWinkler-StuckKPatch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexoleFASEB J20062055655816407457
   PubMed Web of Science ®Google Scholar
• IzumiYSawadaHYamamotoNKumeTKatsukiHShimohamaSAkaikeANovel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicityEur J Pharmacol200755713214017161393
   PubMed Web of Science ®Google Scholar
• IravaniMMSadeghianMLeungCCContinuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory responseExp Neurol200821252253118571649
   PubMed Web of Science ®Google Scholar
• HallEDAndrusPKOostveenJAAlthausJSVonVoigtlanderPFNeuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neuronsBrain Res199674280889117424
   PubMed Web of Science ®Google Scholar
• AndersonDWNeavinTSmithJASchneiderJSNeuroprotective effects of pramipexole in young and aged MPTP-treated miceBrain Res2001905445311423078
   PubMed Web of Science ®Google Scholar
• FujitaYIzawaYAliNPramipexole protects against H2O2-induced PC12 cell deathNaunyn Schmiedebergs Arch Pharmacol200637225726616362428
   PubMed Web of Science ®Google Scholar
• PatteeGLPostGRBennettJPReduction of oxidative stress in amyotrophic lateral sclerosis following pramipexole treatmentAmyotroph Lateral Scler Other Motor Neuron Disord20034909514506939
   PubMed Web of Science ®Google Scholar
• GribkoffFKBozikMEKNS-760704 [(6R)-4,5,6,7-tetrahydro-N6- propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosisCNS Neurosci Ther2008121522618801114
   PubMed Web of Science ®Google Scholar
• GuMIravaniMMCooperJMKingDJennerPSchapiraAHPramipexole protects against apoptotic cell death by non-dopaminergic mechanismsJ Neurochem2004911075108115569251
   PubMed Web of Science ®Google Scholar
• Ferrari-ToninelliGMaccarinelliGUbertiDBuergerEMemoMMitochondria-targeted antioxidant effects of S(−) and R(+) pramipexoleBMC Pharmacol201010220137065
   PubMedGoogle Scholar
• AbramovaNACassarinoDSKhanSMPainterTWBennettJPJrInhibition by R(+) or S(−) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta amyloid peptide in SH-SY5Y neuroblastomaJ Neurosci Res20026749450011835316
   PubMed Web of Science ®Google Scholar
• DanzeisenRSchwalenstoeckerBGillardonFTargeted anti-oxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]J Pharmacol Exp Ther200631618919916188953
   PubMed Web of Science ®Google Scholar
• FrantzSWDemadyDRDaltonJAGottingen minipigs as the nonrodent species in the IND for KNS-760704Int J Toxicol2010291 Abs P17
   Web of Science ®Google Scholar
• AlavianKNDworetzkySIBonanniLEffects of dexpramipexole on brain mitochondrial conductances and cellular bioenergetics efficiencyBrain Res2012144611122364637
   PubMed Web of Science ®Google Scholar
• WangHLarriviereKSKellerKER+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALSAmyotroph Lateral Scler20089505818270879
   PubMed Web of Science ®Google Scholar
• CudkowiczMBozikMEIngersollEWThe effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosisNat Med2011171652165722101764
   PubMed Web of Science ®Google Scholar